Compare Adaptive Biotechnologies Corp (ADPT) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Vanguard High Dividend Yield ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.07 (market cap $3.33B), while Vanguard High Dividend Yield ETF trades at $159.97. The key difference: Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Adaptive Biotechnologies Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | VYM | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $161.17 |
52-Week Low | $10.24 | $132.90 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
VYM trades at $160.14, up 0.41% with a bullish technical outlook supported by moving averages. The ETF focuses on high dividend yield stocks, offering investors steady income through quarterly distributions. Recent news highlights strong investor interest in dividend ETFs for retirement income, with VYM being frequently compared to peers like VIG and SCHD for its diversification and low 0.04% expense ratio.
VYM presents a compelling income-focused investment with stable technical momentum, though RSI levels suggest potential near-term consolidation. The fund's broad diversification across 618 stocks provides resilience, but investors should monitor sector concentration risks and interest rate sensitivity that could impact dividend sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
